Review
doi: 10.1016/j.beha.2021.101248.
Epub 2021 Jan 31.
Perspectives on current survival and new developments in AML
Affiliations
- PMID: 33762103
- DOI: 10.1016/j.beha.2021.101248
Item in Clipboard
Review
Perspectives on current survival and new developments in AML
Best Pract Res Clin Haematol.
2021 Mar.
Abstract
The past three years have witnessed remarkable progress in acute myeloid leukemia (AML). The approval and development of targeted therapies and novel agents has improved outcomes for patients with traditionally poor survival rates. This review has summarized the survival impact of chemotherapy-based regimens in AML and described recent advances that will be of significance in the near future.
Keywords: AML; APR246; Acute myeloid leukemia; Aspacytarabine; BSP-236; CC-486; Eprenetapopt; OS; Oral azacitidine; Overall survival; Venetoclax.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting.J Hematol Oncol. 2023 Mar 3;16(1):17. doi: 10.1186/s13045-023-01411-x. J Hematol Oncol. 2023. PMID: 36869366 Free PMC article.
-
Azacitidine in adult patients with acute myeloid leukemia.Crit Rev Oncol Hematol. 2017 Aug;116:159-177. doi: 10.1016/j.critrevonc.2017.05.010. Epub 2017 Jun 3. Crit Rev Oncol Hematol. 2017. PMID: 28693797 Review.
-
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25. Blood. 2019. PMID: 30361262 Free PMC article.
-
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19. Future Oncol. 2016. PMID: 26785287 Free PMC article.
-
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.Curr Hematol Malig Rep. 2021 Feb;16(1):97-111. doi: 10.1007/s11899-021-00608-6. Epub 2021 Feb 20. Curr Hematol Malig Rep. 2021. PMID: 33609248 Review.
Cited by
-
Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy.Drug Deliv. 2021 Dec;28(1):1166-1178. doi: 10.1080/10717544.2021.1934191. Drug Deliv. 2021. PMID: 34121564 Free PMC article.
-
STAB1 Promotes Acute Myeloid Leukemia Progression by Activating the IKK/NF-κB Pathway and Increasing M2 Macrophage Polarization.Cancer Sci. 2025 Jun;116(6):1508-1521. doi: 10.1111/cas.70044. Epub 2025 Mar 13. Cancer Sci. 2025. PMID: 40083109 Free PMC article.
-
Targeted Drug Delivery for the Treatment of Blood Cancers.Molecules. 2022 Feb 15;27(4):1310. doi: 10.3390/molecules27041310. Molecules. 2022. PMID: 35209102 Free PMC article. Review.
-
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system.Cancer Drug Resist. 2023 Jun 20;6(2):390-415. doi: 10.20517/cdr.2023.16. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37457134 Free PMC article. Review.
-
Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia.PLoS One. 2022 Jul 27;17(7):e0270050. doi: 10.1371/journal.pone.0270050. eCollection 2022. PLoS One. 2022. PMID: 35895695 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
